The MORE Act (HR 5601) would federally decriminalize cannabis by removing it from the Schedule I list of controlled substances under the Controlled Substances Act. It requires federal courts to expunge non-violent cannabis convictions and associated arrests, with a focus on addressing racial disparities in cannabis enforcement. The bill creates an Opportunity Trust Fund that would allocate 50% of funds to criminal justice programs, 20% to small business assistance for minority cannabis entrepreneurs, and 20% to community reinvestment grants for individuals impacted by the War on Drugs. It also prohibits federal agencies from denying benefits or security clearances based on cannabis use or past cannabis convictions, and establishes a Cannabis Justice Office to administer these programs.
The CARE for Moms Act aims to reduce maternal mortality in the United States by improving healthcare access and quality for pregnant and postpartum women, with specific attention to racial disparities. Key provisions include requiring 12-month continuous Medicaid coverage for postpartum individuals (up from 60 days), expanding oral health coverage during pregnancy, and funding State-Based Perinatal Quality Collaboratives through $35 million annual grants. The bill specifically targets the higher maternal mortality rates faced by Black women, who are about 3 times more likely to die from pregnancy-related causes than White women. It also includes provisions for doula services, rural mobile health units, and improved data collection on maternal health outcomes.
The Cutting Copays Act lowers prescription drug costs for low-income Medicare Part D beneficiaries. Starting in 2024, generic drugs will have a $0 copay, while other drugs will have a copay set at the 2023 level (adjusted for prior changes) and then increased annually by the consumer price index. For 2023 and earlier, the maximum copay for generic drugs was $1 and for other drugs was $3. This directly reduces out-of-pocket expenses for millions of low-income seniors and people with disabilities enrolled in Medicare Part D.
This bill requires Medicare to improve transparency in its national coverage decision process for medical treatments and devices. It mandates that Medicare (through the Secretary of Health and Human Services) must determine within 30 days if a submission is a complete request for a coverage decision, and if not, provide specific feedback on missing information. Complete requests must be posted publicly on a government website within two business days, and annual reports must include the time between submission and the point when the request was deemed complete. This directly affects healthcare providers, pharmaceutical companies, and medical device manufacturers seeking Medicare coverage for new treatments.
The Preserving Access to Home Health Act of 2023 repeals a 2018 payment adjustment for Medicare home health agencies, restoring prior payment rates for 2024 and subsequent years. It requires the Medicare Payment Advisory Commission (MedPAC) to analyze how home health agencies' financial performance affects access to care, including reviewing spending and utilization data across Medicare, Medicaid, and other payers. Starting in 2025, the bill mandates home health agencies to report detailed data on visit volumes and payments by payer source (Medicare, Medicaid, private insurers) through updated cost reports. This data will help MedPAC assess payment policy impacts on access to home health services for Medicare beneficiaries.
HR 4712, the Patient Right to Shop Act, prohibits group health plans and health insurance issuers from including contract terms that block third-party tools helping patients compare prescription drug costs. The bill specifically targets contracts with pharmacy benefit managers (PBMs), requiring that plans cannot restrict access to information needed for tools showing all patient costs - like copays, coinsurance, cash prices, or mail-order options. It directly affects patients (who gain clearer cost comparisons), health plans, insurers, and PBMs. The law does not create new tools but ensures existing cost-comparison tools can function by preventing contractual barriers, while clarifying it doesn’t override existing privacy rules like HIPAA.
The Social Security 2100 Act would significantly enhance Social Security benefits for millions of Americans by increasing monthly payments for retirees, disabled workers, widows/widowers, and children. Key provisions include raising the minimum benefit for long-term low earners, improving cost-of-living adjustments using a more accurate index, eliminating the 5-month waiting period for disability benefits, and extending child benefits to age 26. The bill also changes how Social Security taxes are calculated by applying them to income above $400,000 and establishes a unified Social Security Trust Fund to manage program finances. Most provisions would apply to benefits payable from 2025 through 2034, affecting all current and future Social Security beneficiaries.
This bill creates a presumption that minerals from the Democratic Republic of Congo (DRC) containing cobalt and lithium, mined with child or forced labor, cannot be imported into the United States. It requires the U.S. government to develop an enforcement strategy to identify and block such imports, including monitoring supply chains and working with international partners. The bill mandates diplomatic efforts to address child and forced labor in the DRC's mining sector and establishes sanctions against foreign entities that facilitate or engage in such labor practices. The focus is on minerals critical for electric vehicles and electronics, which are heavily sourced from the DRC and processed in China, with specific attention to Chinese mining companies like China Molybdenum that dominate the DRC's cobalt sector.
This bill prohibits Medicare from paying for certain custom-fitted or custom-fabricated orthotic and prosthetic devices delivered via "drop shipment" (direct shipping without in-person training from a qualified provider). It directly affects Medicare beneficiaries who need these devices, ensuring they receive necessary in-person fitting and training. The bill also expands which healthcare professionals (including physical therapists, occupational therapists, orthotists, and prosthetists) can prescribe these devices and updates definitions to clarify terms like "orthoses" and "prostheses." Final regulations implementing these changes must be issued within one year of the bill's enactment.
The Abortion Justice Act of 2023 would establish $350 million in federal grants to support abortion access, including coverage for transportation, lodging, childcare, and direct care services. It would require health care facilities receiving federal funds to provide abortion care and mandate comprehensive coverage for abortion services in all health insurance plans, including Medicaid, Medicare, and private insurance. The bill would also remove barriers for immigrants seeking abortion care, clarify privacy protections for reproductive health information under HIPAA, and prohibit immigration enforcement within 2,000 feet of health care facilities. These provisions would directly affect people seeking abortion care, health care providers, and immigrant communities across the United States.
The ARC Act of 2023 establishes a national program to address peripheral artery disease (PAD), which disproportionately affects minority populations and leads to avoidable amputations. The bill requires Medicare and Medicaid to cover PAD screening tests (such as ankle-brachial index testing) for at-risk beneficiaries without cost-sharing, including people 65+ or those with diabetes, smoking history, or other risk factors. It authorizes $6 million annually for a CDC-led education program to inform healthcare providers and the public about PAD prevention and treatment. The bill also creates quality measures to encourage alternative treatments to amputation and establishes a pilot program to test amputation prevention services at healthcare facilities. These provisions aim to reduce amputation rates and improve outcomes for millions of Americans with PAD.
HR 4073, the Duty Drawback Clarification Act, clarifies U.S. tariff classifications for imported whiskies by creating specific subheadings in the Harmonized Tariff Schedule. It replaces a single tariff line with eight new subheadings that categorize whiskies by type (Irish/Scotch, Bourbon, Rye, or "Other") and container size (under or over 4 liters), each with a uniform duty rate of $2.04 per liter. This change directly affects whiskey importers and manufacturers who must now classify products using these new codes when entering goods into U.S. commerce. The bill streamlines duty calculation and drawback claims (refunds of duties on imported goods later exported) by standardizing the tariff structure for whiskey categories.
